Esophageal cancer is a cancer of the digestive tract. There are two main kinds of esophageal cancer, esophageal squamous cell carcinoma (ESCC), which is more common in Asia, and esophageal adenocarcinoma (EA), which is more common in the U.S. and E.U. ESCC responds well to immune checkpoint inhibitors (ICI) and has several approvals in 2nd-line. Future development is focused on ICI combinations with chemotherapies across multiple lines of treatment for both subgroups.
Oncology Resource Group (ONCrg) is a team of expert analysts who rigorously evaluate the latest corporate reports, news, and data presentations to distill out important advances in complex therapeutic areas. Our comprehensive medical congress coverage, and continuous market surveillance put these advances into the context of an overarching competitive landscape in Esophageal cancer to help guide strategic and tactical commercial development decisions for market participants.